BTIG Reiterates Buy Rating on Cartesian Therapeutics
BTIG maintains its buy rating for Cartesian Therapeutics with a $44 price target, a 362.67% upside from the current price.
Key Points
- BTIG reiterated its buy rating on Cartesian Therapeutics, Inc. (RNAC) with a $44 price target on June 9, 2026.
- BTIG's $44 price target implies 362.67% upside from Cartesian Therapeutics, Inc.'s ($RNAC) current $9.51 share price.
- Shares of RNAC traded near $8.40, with a market cap of $279.4 million and a 52-week range of $5.60 to $15.57.
- Insider activity includes significant purchases and sales, while analysts maintain a strong buy consensus with a mean target of $34.57.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG has reiterated its buy rating on Cartesian Therapeutics, Inc. (NasdaqGM: RNAC), setting a price target of $44. This action occurred on June 9, 2026, as part of BTIG's ongoing analysis of the company.
Analysts Set New Price Targets
On June 9, 2026, BTIG reiterated its buy rating on Cartesian Therapeutics with a target price of $44. Other analysts have also maintained positive outlooks. Needham maintained its buy rating with a $40 target on May 26, 2026, and HC Wainwright & Co. kept its buy rating with a $25 target on May 12, 2026. The consensus among analysts is a strong buy, with a mean target price of $34.57 based on seven opinions.
Other Institutional Activity in Cartesian Therapeutics
Several institutional investors have adjusted their positions in Cartesian Therapeutics. Squarepoint Ops LLC made a substantial increase, adding 2,220,273 shares, bringing its total to 2,238,486 shares valued at about $13.8 million. FMR LLC reduced its holdings by 567,246 shares, now holding 799,743 shares worth $4.9 million. BlackRock, Inc. trimmed its position slightly, selling 10,588 shares to hold 599,108 shares valued at $3.7 million. Vanguard Capital Management LLC entered with 407,597 shares valued at $2.5 million, and 683 Capital Management, LLC boosted its stake by 50,000 shares to 330,000 shares worth approximately $2 million.
Cartesian Therapeutics, Inc. Stock Down 0.9%
Shares of Cartesian Therapeutics, Inc. (NasdaqGM: RNAC) traded near $8.40. The company has a market capitalization of $279.4 million. Its stock has seen a 52-week low of $5.60 and a high of $15.57. The 50-day moving average is $6.95, while the 200-day moving average is $7.72. Cartesian has a current ratio of 7.65 and a quick ratio of 7.46, indicating strong liquidity.
Insider Buying and Selling at Cartesian Therapeutics, Inc.
Recent insider activity at Cartesian Therapeutics included both buying and selling. On April 2, 2026, Elizabeth Hoge purchased 758,001 shares and sold 22,740 shares. Similarly, Murat Kalayoglu bought 758,001 shares and sold 22,740 shares on the same date. Additionally, Michael Singer sold 6,555 shares on March 13, 2026, and Christopher Jewell, the Chief Scientific Officer, sold 9,000 shares at an average price of $7.66 on January 13, 2026.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., headquartered in Frederick, Maryland, is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. Its lead product, Descartes-08, is an mRNA CAR-T cell therapy in Phase 2b trials for treating autoimmune diseases like generalized myasthenia gravis and systemic lupus erythematosus. The company is also advancing Descartes-15, an early-stage therapy for multiple myeloma. Cartesian is led by CEO Dr. Carsten Brunn and employs approximately 75 people.
Bottom Line
BTIG's reiterated buy rating with a $44 target reflects continued confidence in Cartesian Therapeutics' potential. Investors track these updates to gauge market sentiment and company prospects. Remember, analyst ratings are one of many tools investors use, and this reiteration is part of a larger picture of Cartesian's market position.
Get Cartesian Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RNAC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.